Norges Bank, the central bank of Norway, reports beneficial ownership of Celanese Corp common stock on a passive basis. It reports holding 9,645,359 shares, representing 8.7955% of the outstanding common stock.
Norges Bank has sole voting power over 9,342,811 shares and no shared voting power. It has sole dispositive power over 9,342,811 shares and shared dispositive power over 302,548 shares. Certain shares are invested on behalf of the Government of Norway.
Celanese Corporation reported Q2 2026 net sales of $2,752 million, up from $2,532 million a year earlier. Net earnings attributable to Celanese were $125 million, with diluted EPS of $1.13 versus $1.80. For the first half, net sales reached $5,089 million and net earnings attributable to Celanese were $169 million.
Operating cash flow for the first six months was $285 million, while investing activities provided $366 million, helped by $493 million of proceeds from the Micromax business sale, which generated a $50 million gain. Financing uses totaled $549 million, including $621 million of long-term debt repayments. As of June 30, 2026, cash was $1,364 million and long-term debt, including current installments, carried at $12,013 million, with a $1.75 billion U.S. revolving credit facility fully available.
The company incurred $59 million of exit and shutdown costs tied mainly to closing its Lanaken, Belgium facility and expects an additional $60 million through 2027. Environmental remediation liabilities totaled $66 million, which management does not expect to be material to financial position. A quarterly dividend of $0.03 per share, totaling $3 million, was declared for payment in August 2026.
Celanese Corporation reported second quarter 2026 adjusted earnings per share of $2.45, including about $0.35 per share of non-cash transaction amortization, its highest level in nearly three years. Companywide operating EBITDA grew by more than 20% versus the prior-year period.
Engineered Materials delivered adjusted EBIT of $234 million and operating EBITDA of $335 million, with margins of 16% and 23%. Growth platforms performed strongly, with medical net sales up 19% and electronics up 11% year-over-year, while portfolio and footprint actions are expected to drive about $30 million of annualized cost savings and double-digit full-year adjusted EBIT growth despite inventory and divestiture headwinds.
The Acetyl Chain generated adjusted EBIT of $321 million and operating EBITDA of $385 million, at margins of 24% and 29%, as net sales rose 28% sequentially and 19% year-over-year, led by Western Hemisphere vinyl chain strength. Free cash flow was $140 million in the quarter, and management now targets 2026 free cash flow of $700–$800 million. The company repaid $508 million and $400 million of 2026 bonds using cash on hand and ended the quarter with total debt of $12.0 billion and net debt of $10.6 billion. Third quarter 2026 adjusted EPS is guided to approximately $1.35–$1.75, with full-year adjusted EPS expected to be about $6.00.
Celanese Corporation reported strong second quarter 2026 results, with net sales of $2,752 million and U.S. GAAP diluted earnings per share of $1.15 and adjusted earnings per share of $2.45, its highest adjusted EPS in nearly three years. Net sales increased 18 percent sequentially, driven by a 4 percent volume increase and a 14 percent price increase. Consolidated operating profit was $276 million, adjusted EBIT $470 million, and operating EBITDA $649 million, at margins of 10, 17, and 24 percent, respectively.
Engineered Materials delivered net sales of $1,446 million and operating EBITDA of $335 million with a 23 percent margin, supported by favorable pricing and mix and growth in medical and electronics. The Acetyl Chain generated net sales of $1,329 million and operating EBITDA of $385 million with a 29 percent margin, reflecting pricing and volume gains. Portfolio and footprint actions, including the Ulsan compounding closure, nylon 6,6 optimization, and planned Lanaken acetate tow closure, are expected to provide more than $50 million of annualized fixed-cost savings.
Operating cash flow for the quarter was $209 million and free cash flow was $140 million. Cash and cash equivalents totaled $1,364 million against total debt of $12,007 million, with net debt of $10,643 million as deleveraging remains a priority. For the third quarter, management projects adjusted EPS of approximately $1.35 to $1.75, and for full year 2026 it continues to expect about $6.00 of adjusted EPS and $700 to $800 million of free cash flow.
Celanese Corporation reports that its wholly owned subsidiary Celanese US Holdings LLC entered into a First Amendment to its Revolving Credit Agreement dated August 11, 2025. The amendment applies from the fiscal quarter ending March 31, 2027 through the facility’s maturity.
The amendment increases the consolidated net leverage ratio financial covenant level to 5.50:1.00, with modified step‑down levels thereafter. It also increases the combined negative covenant baskets for debt incurred by foreign subsidiaries for acquisitions and by Chinese subsidiaries for corporate purposes from $900 million to $1,050 million, and makes additional technical changes.
Celanese Corp removal notice: the New York Stock Exchange filed a Form 25 to withdraw the listing and registration of the class described as the Guarantor of 4.777% Senior Notes Due 2026. The Exchange states it complied with Rule 12d2-2 procedures and the issuer complied with Exchange rules governing voluntary withdrawal.
Celanese Corporation, through its wholly owned subsidiary Celanese US Holdings LLC, has initiated the redemption of all outstanding 4.777% Senior Notes due July 19, 2026. The company issued a formal notice of redemption under the governing indenture.
The redemption is expected to occur on June 25, 2026. Holders will receive a redemption price equal to 100% of the principal amount of the Notes being redeemed, plus any accrued and unpaid interest up to the redemption date.
Celanese Corp. ownership disclosure: Capital Research Global Investors filed an amendment reporting beneficial ownership of 4,696,916 shares of Celanese common stock, equal to 4.2% (as of 03/31/2026) of the 111,922,758 shares the filer believes are outstanding. The filing attributes sole voting and sole dispositive power over all reported shares to the filer.
Chinn Bruce E. reported acquisition or exercise transactions in this Form 4 filing.
Celanese Corp director Bruce E. Chinn received an annual equity grant of 2,975 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost to him under the Company's Amended and Restated 2018 Global Incentive Plan and vest in full on the one-year anniversary of the grant date.
After this compensation-related grant, Chinn directly holds 7,261 shares of Celanese common stock. This filing reflects routine director equity compensation rather than an open-market purchase or sale.
Celanese Corp director Anne P. Noonan reported receiving a grant of 2,975 shares of common stock as a compensation award. The Form 4 shows this as a grant or award acquisition at a price of $0.00 per share, bringing her directly held position to 2,975 shares.
A footnote explains this is an annual grant of restricted stock units under Celanese’s Amended and Restated 2018 Global Incentive Plan, which vest in full on the one-year anniversary of the grant date.